All In Biotech

NDA 217512 · Baxter Hlthcare Corp

Pantoprazole Sodium In 0.9% Sodium Chloride

Pantoprazole Sodium · Intravenous

Last checked: Nov 19, 2026Latest source record: Feb 14, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Feb 14, 2024

Approved uses

1

Original approval plus efficacy supplements

Registered trials

231

49 Phase 3, 17 recruiting

FAERS reports

63,382

51,028 serious, 7,825 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 14, 2024.

Pantoprazole sodium is a proton pump inhibitor (PPI) indicated in adults for the following: • Short-term treatment (7 to 10 days) of gastroesophageal reflux disease (GERD) associated with a history of Erosive Esophagitis (EE). ( 1.1 ) • Pathological hypersecretion conditions including Zollinger-Ellison (ZE) Syndrome. ( 1.2 ) 1.1 Gastroesophageal Reflux Disease Associated with a History of Erosive Esophagitis Pantoprazole sodium in 0.9% sodium chloride injection is indicated for short-term treatment (7 to 10 days) of adult patients with gastroesophageal reflux disease (GERD) and a history of erosive esophagitis (EE). Safety and efficacy of pantoprazole sodium in 0.9% sodium chloride injection as a treatment of patients with GERD and a history of EE for more than 10 days have not been demonstrated. 1.2 Pathological Hypersecretion Including Zollinger-Ellison Syndrome Pantoprazole sodium in 0.9% sodium chloride injection is indicated for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome in adults.

Mechanism: Pantoprazole is a PPI that suppresses the final step in gastric acid production by covalently binding to the (H + , K + )-ATPase enzyme system at the secretory surface of the gastric parietal cell. This effect leads to inhibition of both basal and stimulated gastric acid secretion irrespective of the stimulus. The binding to the (H + , K + )-ATPase results in a duration of antisecretory effect that persists longer than 24 hours for all doses tested (20 mg to 120 mg).

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE · PANTOPRAZOLE SODIUM EQ 80MG BASE/100ML (EQ 0.8MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
  • PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE · PANTOPRAZOLE SODIUM EQ 40MG BASE/100ML (EQ 0.4MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
  • PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE · PANTOPRAZOLE SODIUM EQ 40MG BASE/50ML (EQ 0.8MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Pantoprazole" as an intervention, any sponsor and status, largest first.

All 231 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue7,509
  • off label use6,452
  • dyspnoea6,186
  • pain6,112
  • drug ineffective5,859
  • diarrhoea5,757
  • nausea5,700
  • headache5,314
  • arthralgia4,977
  • pyrexia4,872
  • rash4,405
  • vomiting4,179

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004195
2005655
2006888
2007965
20081,224
20091,189
2010664
2011794
2012759
2013348
2014472
20151,589
20161,762
20171,808
20182,570
20192,988
20203,530
20215,120
20228,294
20236,925
20248,232
20257,486
20264,924

Recalls

1 FDA enforcement reports for this application.

  • Aug 6, 2026 · Class II · Ongoing

    CGMP Deviations

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 616 on PubMed

Sponsor: Baxter Hlthcare Corp

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.